Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$25.10
-$0.81(-3.13%)
At close: 4:00 PM EDT
$25.10
-$0.81(-3.13%)
Day’s Range― - ―
52-Week Range$15.60 - $38.26
Previous CloseN/A
Volume1.81M
Average Volume (3M)2.52M
Market Cap
$2.63B
Enterprise Value$1.50K
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$247.36M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 09, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding102,879,210
10 Day Avg. Volume2,330,625
30 Day Avg. Volume2,517,261
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.50Price Target Upside109.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.39
Revenue Forecast (FY)$56.97M
Bulls Say, Bears Say
Bulls Say
Proprietary Base-editing PlatformBeam’s base-editing technology is a durable competitive asset: a platform approach enables multiple therapeutic programs, recurring collaboration/licensing revenue streams, and partner-driven scale. Platform breadth supports long-term optionality across genetic diseases and oncology.
Relative Balance-sheet StrengthManageable leverage and sizable equity give Beam financial flexibility critical for funding multi-year clinical programs without immediate insolvency risk. A stronger balance sheet reduces short-term refinancing pressure and supports strategic partnerships or milestone-driven financing.
Advancing Pipeline And Regulatory ProgressConcrete clinical and regulatory milestones materially de-risk programs: pivotal dosing, IND clearance, and completed trial cohorts increase probability of near-term readouts and filings. Progress toward BLA for partnered risto-cel could transition Beam toward sustainable product revenue.
Bears Say
High Cash BurnPersistent negative operating and free cash flow creates ongoing funding needs that can force dilution or debt financing. For a pre-commercial biotech, sustained cash burn means management must prioritize financing or partnerships, which can constrain strategic optionality.
Ongoing Negative ProfitabilityRecurrent losses and negative operating margins indicate the company has not reached scalable economics. Until products reach commercialization or partnerships produce material milestone revenue, continued losses will erode equity and limit reinvestment capacity.
Revenue Dependent On CollaborationsRevenue concentration in upfront, milestone, and royalty arrangements yields lumpy and partner-dependent cash flows. Without own commercial products, sustainable revenue growth and margin expansion remain contingent on external partners and successful program handoffs.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics, Inc.’s price range in the past 12 months?
Beam Therapeutics, Inc. lowest stock price was $15.60 and its highest was $38.26 in the past 12 months.
What is Beam Therapeutics, Inc.’s market cap?
Beam Therapeutics, Inc.’s market cap is $2.63B.
When is Beam Therapeutics, Inc.’s upcoming earnings report date?
Beam Therapeutics, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 92 days.
How were Beam Therapeutics, Inc.’s earnings last quarter?
Beam Therapeutics, Inc. released its earnings results on Aug 04, 2026. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.106 by -$0.074.
Is Beam Therapeutics, Inc. overvalued?
According to Wall Street analysts Beam Therapeutics, Inc.’s price is currently Undervalued.
Does Beam Therapeutics, Inc. pay dividends?
Beam Therapeutics, Inc. pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics, Inc. dividends here
What is Beam Therapeutics, Inc.’s EPS estimate?
Beam Therapeutics, Inc.’s EPS estimate is -1.15.
How many shares outstanding does Beam Therapeutics, Inc. have?
Beam Therapeutics, Inc. has 102,879,210 shares outstanding.
What happened to Beam Therapeutics, Inc.’s price movement after its last earnings report?
Beam Therapeutics, Inc. reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.106. Following the earnings report the stock price went up 9.417%.
Which hedge fund is a major shareholder of Beam Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.50 (109.16% Upside)
$52.50 (109.16% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 71%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics, Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Stock 12 Month Forecast
Average Price Target
$52.50
▲(109.16% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.37% Insiders
21.84% Mutual Funds
5.13% Other Institutional Investors
40.52% Public Companies and Individual Investors